Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 783

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 783
---
vingdrug therapies to treat rare and complex central nervous system disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as attention deficit hyperactivity disorder (“ADHD”). The Company’s lead product candidates are Quilience, to treat narcolepsy (type 1 and type 2), and Nolazol, to treat ADHD. On February 2, 2021, the Company completed the closing of its initial public offering (the “Initial Public Offering”) of 4,819,277units at a price of $ 4.15per unit. Each unit consisted of one common share and one warrant to purchase one common share (the “Warrants”).The common shares and Warrants were immediately separable from the units and were issued separately. The common shares and Warrants began trading on the Nasdaq Capital Market on January 29, 2021 under the symbols “NLSP” and “NLSPW,” respectively. The Company received net proceeds of $ 17million, after deducting underwriting discounts and commissions and other estimated offering expenses. The Warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $ 4.15per share. In addition, the Company granted the underwriters a 45 -dayoption to purchase up to an additional 722,891common shares and/or Warrants to purchase 722,891common shares at the public offering price of $ 0.01per Warrant, of which the underwriters exercised its option to purchase Warrants to purchase up to 722,891common shares. These Warrants were issued in the Company’s Initial Public Offering and therefore have the same exercise price of $ 4.15per share. Going Concern As of December 31, 2023, the Company had an accumulated deficit of approximately $ 70.4million and the Company incurred an operating loss for the year ended December 31, 2023, of approximately $ 11.8million. To date, the Company has dedicated most of its financial resources to achieve and maintain Phase 3 readiness, research and development, clinical studies associated with its ongoing biopharmaceutical business and general and administrative expenses. As of December 31, 2023, the Company’s cash and cash equivalents were $ 0.9million. The Company’s existing cash and cash equivalents and access to existing financing arrangements will not be sufficient to fund operations for a period of one year from